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Abstract
Microarray gene-expression data of 54 paired gastric cancer and adjacent noncancerous gastric tissues were analyzed, with
the aim to establish gene signatures for cancer grades (well-, moderately-, poorly- or un-differentiated) and stages (I, II, III
and IV), which have been determined by pathologists. Our statistical analysis led to the identification of a number of gene
combinations whose expression patterns serve well as signatures of different grades and different stages of gastric cancer. A
19-gene signature was found to have discerning power between high- and low-grade gastric cancers in general, with overall
classification accuracy at 79.6%. An expanded 198-gene panel allows the stratification of cancers into four grades and
control, giving rise to an overall classification agreement of 74.2% between each grade designated by the pathologists and
our prediction. Two signatures for cancer staging, consisting of 10 genes and 9 genes, respectively, provide high
classification accuracies at 90.0% and 84.0%, among early-, advanced-stage cancer and control. Functional and pathway
analyses on these signature genes reveal the significant relevance of the derived signatures to cancer grades and
progression. To the best of our knowledge, this represents the first study on identification of genes whose expression
patterns can serve as markers for cancer grades and stages.
Citation: Cui J, Li F, Wang G, Fang X, Puett JD, et al. (2011) Gene-Expression Signatures Can Distinguish Gastric Cancer Grades and Stages. PLoS ONE 6(3): e17819.
doi:10.1371/journal.pone.0017819
Editor: Amanda Toland, Ohio State University Medical Center, United States of America
Received November 24, 2010; Accepted February 9, 2011; Published March 18, 2011
Copyright:  2011 Cui et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported in part by National Science Foundation (DEB-0830024, DBI-0542119), the National Institutes of Health (1R01GM075331), a
‘‘Distinguished Scholar’’ grant from the Georgia Cancer Coalition, and a seed fund jointly from the President’s Venture Fund and the Office of the Vice President
for Research of the University of Georgia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation oft h e
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: xyn@bmb.uga.edu
Introduction
Cancer grading is a measure of a cancer’s malignancy and
aggressiveness. A popular grading system uses four levels of
malignancy (G1-G4), reflecting the combined level of cell-
appearance abnormality, deviation in growth rate from the
normal cells and the degree of invasiveness and dissemi-
nation. These pathological measures have been found to be
in general concordance with the level of cellular differen-
tiation (American Joint Commission on Cancer) [1]. Hence
{G1, G2, G3, G4} are also referred to as well-, moderately-,
poorly- and un-differentiated, respectively. As of now, there has
not been a universal grading system for all cancers. Instead,
different grading systems have been proposed for different
cancers. For example, the Gleason system [2] is probably
the most well-known for grading adenocarcinoma cells in
prostate cancer while the Bloom-Richardson system [3] is
used for breast cancer, and the Fuhrman system [4] is used for
kidney cancer.
Gastric cancer, the second leading cause for cancer-related
death worldwide, is particularly prevalent in Asian countries,
including China, Korea and Japan [5]. In the U.S., this
asymptomatic disease had ,21,500 new cases in 2008 along
with 10,800 deaths [6]. Unlike other cancers, gastric cancer does
not yet have a generally accepted grading scheme. Grading has
been mostly done based on rather general cancer-grading
guidelines from organizations like the American Joint Commis-
sion on Cancer. There are a few systems for classifying gastric
cancers into histological subtypes, including those by the Lauren
[7], the World Health Organization (WHO) [8] and Goseki,
et al. [9,10], which define subtypes according to the structural
features of the cancer, the histopathological appearances of the
cells, and the level of mucus, respectively. However, it is largely
controversial regarding whether any of these systems is really
relevant to the degree of malignance and survivability, thus
having not been widely used for grading gastric cancer [11].
The lacking of a well-established grading system for gastric
cancer remains as a major obstacle hindering the progress in
this field.
We present a computational study herein, aimed to identify a
set of genes whose expression patterns can well distinguish
among gastric cancers of different grades, like Oncotype DX, a
21-gene panel for identifying low-risk breast cancer [12]. These
genes, whose expression patterns distinguish gastric cancers of
different grades, provide useful information towards developing
a gene expression-based grading system for gastric cancer. In
addition, we also present our findings on the gene expression
patterns common to cancers at different developmental stages,
potentially serving as molecular signatures for gastric cancer
staging.
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A. Identification of genes with expression changes
correlated with cancer grades
17,800 human genes were profiled in this study, using
Affymatrix Exon Arrays. Out of the 54 cancer samples, 8 are
well differentiated (WD), 9 moderately differentiated (MD), 35
poorly differentiated (PD) and 2 undifferentiated (UD). A total of
452 genes were found to be differentially expressed as determined
using the following criteria: the expression levels in cancer and the
corresponding control tissue show at least 2-fold change, and the
statistical significance, P-value, of having this level of expression
change is ,0.05 (see Material and Methods; gene names are listed
in Table S1). Among the 452 genes, 97 uniquely in UD, 62 in PD,
8 in MD and 16 uniquely in WD represent a core set of differentially
expressed genes, which are consistently identified by applying
different classification strategies using the paired-sample informa-
tion or not. This set includes genes exhibiting the most consistent
expression change (over 2-fold) in cancer versus control tissues,
which were deemed to be differentially expressed genes with high
reliability, derived through multiple statistical tests. In contrast, the
whole set of 452 genes represent an extended set. We noted that
there is a general trend that the number of the differentially
expressed genes increases as a gastric cancer, relative to normal
tissue, is more poorly differentiated, as shown in Figure 1. This
observation is in agreement with our general knowledge that less-
differentiated cancers tend to have more differentially expressed
genes and are more aggressive; the exception for WD, as shown in
Figure 1, might reflect the small sizes of the WD and the MD
groups.
We then checked if some genes may have their expression
changes correlate with the cancer grades. To do this, we have
calculated the Spearman correlation coefficient (CC) between the
average expression of each gene across all samples of each grade
and the four cancer grades. It was found that the expression
changes of 99 genes correlate perfectly with the grades WD-MD-
PD-UD (|CC|=1, P-value,0.05) (see details in Table S2).
Among these genes are POF1B, MET, CEACAM6, ZNF367,
GKN1, LIPF, SLC5A5, MUC13, CLDN1, MMP7 and ATP4A,
which are all known to be cancer related. Figure 2 shows four
examples with either positive or negative correlations. Among
them, MUC13 has been reported as a good marker for the level of
differentiation of gastrointestinal mucosa [13]. Increased MUC13
expression has been found to induce morphological changes,
including scattering of cells through interference with the function
of cell adhesion molecules [14]; thus, an increased expression
along with differentiation may indicate enhanced cell-cell
adhesion.
We noted that genes with their expression changes correlated
with cancer grades are highly enriched among secreted or
membrane proteins (P-value ,0.05), which participate in multiple
signaling pathways such as ErbB, FAS, NOD-like receptor, PPAR
and Wnt signaling, as well as cell adhesion molecules (CAMs) and
tight junctions. This is not surprising since these pathways are
essentially involved in cell growth and cell death, as well as cancer
metastasis. Such changes in gene-expression patterns of these
pathways, involved in signal transduction and extracellular
communication, may provide clues about cancer progression.
B. Identification of gene signatures for cancer grades
We have examined the 452 differentially-expressed genes,
aiming to identify genes whose expression patterns can, with good
accuracy and reliability, distinguish gastric cancers of different
grades. The classification analysis (see Methods) was first
conducted between two cancer groups (highly and poorly
differentiated), and then extended to five groups, namely four
cancer grades and the control. A support vector machine (SVM)-
based regressive feature elimination approach was applied, using a
linear kernel for cancer classification (see Methods).
At the end, a 19-gene group was identified which can
distinguish between highly and poorly differentiated cancers with
an overall agreement at 79.2%, based on the expression fold-
change in cancer versus control tissues. Similarly, a 198-gene group
can distinguish among the four different cancer grades and the
control group according to their gene expression, giving rise to
74.2% overall classification accuracy. Both gene sets were chosen
Figure 1. Relationship between cancer grades and the number of differentially expressed genes, with fold-change (FC) .=2 and P-
value ,0.05 by Wilcoxon signed–rank test (blue), using paired sample information, and fold-change test defined in this study (red),
without using paired-sample information. The green plot shows the overlapped identification between these two strategies.
doi:10.1371/journal.pone.0017819.g001
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the classification results on 500 sets randomly sampled from the 54
sample sets, along with their significance ranking (see Methods for
details).
The 19-gene signature consists of ADIPOQ, COL6A3, TNS1,
SCN7A, DES, VIL1, COL3A1, C2orf40, SMYD1, ACTG2,
MEIS1, C7, GPR174, SHCBP1, DUSP1, DNAJB5, HIATL1,
IL17RB, and FAT. A close look at the functional annotation of
these genes revealed that their protein products are involved in cell
growth and differentiation (IL17RB, SMYD1, SHCBP1), cell
motility (ACTG2), angiogenesis and tissue remodeling (ADIPOQ),
carcinogenesis (ECRG4), matrix protein synthesis (COL3A1,
COL6A3), and others like G protein-coupled receptor 174
(GPR174), brush border cytoskeleton (VIL1), membrane attack
complex (C7), and sodium channel (SCn7A).
17 out of the 19 genes, plus an additional 181 genes, form a 198-
gene group whose expression pattern can distinguish the four
cancer grades and the control. Their functions cover cell division,
immune response, signal transduction and transcription regula-
tion, in addition to the aforementioned categories. Overall, 39 out
of 99 grade-correlated genes are part of this 198-gene signature,
including CLDN1, MUC13, VIL1, HIATL1, CDCA7,
HIST1H2BM and FAT (see the full list in Table S3).
In addition to this catch-all signature for five-way classification,
we also identified and analyzed grade-specific gene signatures for
each cancer grade. For example, LAPTM4B is one such
representative. This gene gives high classification accuracy for
caner and control samples in the WD group with the AUC (area
under curve) =0.97 (Figure 3). Using 7.04 as the expression cutoff,
this gene can well distinguish cancer from the control samples in
the WD group with sensitivity =87.5% and specificity =100%.
This result is not surprising since it is known that LAPTM4B is
essential for cell growth and survival, and its up-regulation has
been found to be correlated with the level of differentiation of
hepatocellular carcinoma [15]. In total, 40 such signature genes
are found specifically for the WD group; 18, 20 and 255 genes are
specific to the MD, PD and UD group, respectively (see details in
Table S4).
We have also identified single gene discriminators for each
grade group against the rest of the samples, including the control,
as summarized in Table 1. For instance, the signatures for the PD
group include the up-regulated genes, MYO1B for WD; GKN2 for
MD; CTSA for PD; and a down-regulated gene, RHOJ, for the UD
group. These single-gene discriminators show significant AUCs,
ranging from 0.76 to 0.99, while the overall classification
accuracies obtained by 5-fold cross-validation range from 70.0%
to 97.0% for different groups. A subsequent search for k-gene
combinations (k=2, 3, 4) for each cancer group by exhaustively
going through all the combinations of k-gene groups also
identified.
C. Identification of gene signatures for pathological stage
Using similar analyses to those of the above, we have identified
gene signatures for early stage (stage I+II) and advanced stage
cancer (stage III+IV). Table 2 highlights the most discriminative
single gene markers, with the classification accuracy ranging from
75.0% to 81.4%. Multi-gene signatures were also checked for
cancer staging. For example, two signatures were found to be
particularly effective in cancer staging, namely a 10-gene group
(CPS1+ DEFA5+ DES+ DMN+ GFRA3+ MUC17+ OR9G1+
REEP3+ TMED6+ TTN) and a 9-gene group (DPT+ EIF1AX+
FAM26D+ IFITM2+ LOC401498+ OR2AE1+ PRRG1+
REEP3+ RTKN2), which can distinguish the early and the
advanced gastric cancers from the remainder of the samples
Figure 2. Correlation between gene expression levels and cancer grades of four genes. (‘‘q’’ and ‘‘Q’’ denote up- and down-regulation in
cancer versus reference tissues, respectively.)
doi:10.1371/journal.pone.0017819.g002
Figure 3. The ROC curve of LAPTM4B as a discriminator
between cancer and control samples in the WD group (with
AUC of 0.97).
doi:10.1371/journal.pone.0017819.g003
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respectively. The overall classification accuracy on the three
groups, early, advanced and control, is 71.4%.
A functional analysis on these signature genes revealed
something interesting. For example, among the protein products
of early-stage signature genes, GFRA3, MUC17, OR9G1, REEP3
and TMED6 are membrane proteins, mostly receptors that
transduce extracellular signals. DEFA5 is a microbicidal peptide
believed to be involved in host defense that is highly expressed in
the ileum [16]. CPS1, DES and TTN are involved in multiple
metabolic processes, muscle function and the M phase of the
mitotic cell cycle, respectively. We speculate that these signaling-
and immune- related genes may represent the early abnormality of
tissue cells during oncogenesis in general.
A few genes were found to be in both the cancer grading and
staging signatures, such as CPS1, DES, GFRA3, TMED6 and
DPT, indicating some biological relevance between cancer
differentiation and progression. We then examined whether the
gene expression of staging signatures are associated with
pathological stages. Among them, those highly correlated with
different pathological stages are LANCL3, MFAP2 and PPA1
(Figure 4), showing consistent up- and down-regulation, respec-
tively, along with cancer progression.
D. Identification of differentially-expressed genes
independent of cancer grades and stages
In addition to the differential expression specific to certain
subgroups of gastric cancer, we also examined if some genes are
differentially expressed in gastric cancer in general, regardless of
grades and stages. 62 such genes were found with consistent
differential expression by at least 2-fold changes in cancer versus
corresponding reference tissues. We noted that they are mostly
involved in extracellular processes such as focal adhesion, CAMs,
tight junction, cytokine-cytokine receptor interaction and ECM-
receptor interaction, the plasminogen activation cascade, as well as
signaling pathways including Wnt signaling and Integrin signaling,
which are closely relevant to cell growth and cell proliferation
control. Searching against our in-house database (http://bioin
fosrv1.bmb.uga.edu/DMarker/) which includes public microarray
datasets from GEO [17], Oncomine [18] and SMD [19], covering
over 53 human diseases including cancer, we found that the
differential expression patterns of 15 genes are highly specific to
gastric cancer, such as GKN2, CLDN7, THY1, GIF and PGA4,
while most others are general to multiple cancer types. For
example, the most general ones include a few members of the
collagen gene family (COL1A2, COL3A1 and COL1A1), the
carcinoembryonic antigen–related cell adhesion molecule (CEA-
CAM6), matrix metalloproteinases (MMP1, MMP7 and MMP12),
topoisomerase (TOP2A) and secreted phosphoprotein (SPP1).
Only three, CLDN7, CLDN1 and DPT, of these genes are
significantly differentiated in all grades or stages of gastric cancer.
Table 1. The top three discriminative genes for each grade
(against the rest), through classification analysis based on
both their expression levels (*P-value is obtained by Wilcoxon
signed–rank test; ‘‘Q’’ denotes a down-regulated gene; REL
means ‘‘raw expression level’’).
Subtype REL-based signatures
Genes AUC *P-value
Classification
Acc. (sen./spe.)%
WD MYO1B 0.85 1.07E-03 81.5(75.0/82.6)
MET 0.84 1.33E-03 80.9 (62.5/84.1)
EDARADDQ 0.83 1.70E-03 72.3(85.7/69.7)
MD GKN2 0.77 1.42E-02 74.3(77.8/74.0)
SPP1 0.83 4.94E-04 75.7(66.7/76.3)
PDIA2 0.87 7.82E-04 70.2(77.8/68.7)
PD CTSA 0.76 1.21E-06 75.8 (87.5/62.0)
ADAMTS12 0.79 6.81E-08 75.0 (75.0/75.0)
CST2 0.78 1.77E-07 74.2 (78.1/69.4)
UD COTL1 0.99 3.33E-01 96.4(100/96.4)
RHOJQ 0.99 3.33E-01 97.1(100/97.1)
TNFRSF1B 0.99 3.33E-01 97.1(100/97.1)
doi:10.1371/journal.pone.0017819.t001
Table 2. The most discriminative genes identified for staging through classification analysis based on both their expression level
and expression fold-change (*P-value is obtained by Wilcoxon signed–rank test; ‘‘Q’’ denotes a down-regulated gene. ‘‘–‘‘ is
included since the ECMs based on fold-change is applicable to both early and advanced stages; REL means ‘‘raw expression level’’
while EFC means ‘‘expression fold-change’’).
Stage REL-based signatures EFC-based signature
REMs AUC P-value
Classification
Acc.(sen./spe.)% ECMs AUC P-value
Classification
Acc.(sen./spe.)%
I+II CHRM3Q 0.83 3.36E-04 79.3(90.9/67.4) GNG5 0.86 2.06E-04 83.2(100/64.4)
PCDH7Q 0.82 3.78E-04 78.9(91.9/66.7) DKK2 0.74 1.08E-02 78.4(81.8/74.6)
TACR2 0.78 2.40E-03 78.5(100/56.6) KIF2B 0.79 2.69E-03 76.8(81.8/71.2)
SATB2 0.82 4.64E-04 77.0(81.8/72.1) C3orf20 0.77 4.99E-03 76.8(72.7/81.4)
LANCL3Q 0.78 2.28E-03 0.77(0.91/0.62)
PPA1 0.80 1.14E-03 0.75(0.82/0.69)
III+IV RTKN2 0.54 2.88E-11 81.4(71.1/88.9) – – –
PKM2 0.63 2.25E-10 79.3(69.5/86.4) – – –
B4GALNT2 0.52 5.14E-09 77.8(83.1/74.1) – – –
MFAP2 0.62 5.73E-09 77.1(66.1/85.2) – – –
doi:10.1371/journal.pone.0017819.t002
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are highly expressed in cancer versus control samples across all
grades and stages, with a moderate increase in early cancer tissues,
while DPT was down-regulated across all these groups. The
consistent expression pattern across all the cancer subgroups may
indicate that these genes participate in many major biological
pathways involved in cancer formation and progression. As is well
known, the two claudin proteins, claudin-1 and claudin-7, are
integral membrane proteins crucial to formation of tight junctions,
maintaining cell-to-cell adhesion and regulating paracellular and
transcellular transport of solutes across human epithelia and
endothelia, which are differentially expressed in various cancers
such as cervical neoplasia [20], renal carcinoma [21] and an
intestinal type of gastric cancer [22]. Dermatopontin (DPT)i sa n
extracellular matrix protein serving as a communication link
between the dermal fibroblast cell surface and its extracellular
matrix. Its reduced expression has also been found in both uterine
leiomyomas and keloids [23]. The ROC shown in Figure 5C
indicates that these genes could possibly be used as effective
markers for gastric cancer diagnosis in general.
E. Verification of the identified signatures on public
datasets
The expression patterns of our identified signature genes were
checked against two public datasets, namely, the Kim and Takeno
datasets (see Materials and Methods), to determine the generality
of these gene signatures. As shown in Figure 6, the distribution of
expression differentials between our data and the Kim dataset is
significantly concordant, indicating that the general applicability
of our identified markers. Out of 19 and 12 overlapped genes from
the above-identified grades-correlated and stage-correlated gene
list, 10 and 5 show similar expression patterns across cancers of
G1-2/G3-4 grades and I-IV stages in the Kim data, respectively,
reflecting a high consistence in expression patterns of these genes
among different sample sets.
Overall, our 19-gene signature for cancer grades performed well
on the Kim data and obtained 78.0% classification accuracy on 5-
fold cross validation in terms of distinguishing poorly from highly
differentiated cancers. Similarly, the two-stage signatures (10-gene
and 9-gene groups) obtained respective accuracies of 84.0% and
76.0% on the Kim dataset. The 198-gene signature was not
checked since the Kim dataset provides only fold-change instead of
raw expression data.
Interestingly, we noted that there is moderate correlation
between the gene expression of our identified signature groups and
cancer recurrence based on the peritoneal relapse information of
Takeno’s data [24]. Specifically, the four signatures, 19-, 198-, 10-
and 9-gene groups, can predict the peritoneal relapse with an
overall accuracy of 66.0%, 87.2%, 73.0% and 55.3%, respectively,
by distinguishing between the relapse-free and peritoneal-relapse
patients in Takeno’s study [24].
Discussion
Microarray gene-expression analyses on gastric cancer have
previously identified gene expression patterns for prognosis
prediction [25,26] and general cancer diagnosis [27,28] (as
reviewed in Table S6) but none for gastric cancer subtyping or
grading. Here, we presented an analysis on 54 pairs of cancer and
adjacent reference tissues from the same number of gastric cancer
patients, and identified molecular signatures for cancer grades and
stages.
It is known that different classification and gene selection
analyses may lead to different gene signatures, posing a serious
issue about the stability and usefulness of the selected gene
signatures. To deal with this issue, we have applied exhaustive
searches for k-gene signatures (k,=4) coupled with a robust
feature selection procedure with majority voting for k.4, which
ensures the stability of the identified signature genes. On the other
hand, due to the complex nature of cancer gene-expression data, a
general belief has been that different classification techniques may
give rise to different signatures but of equal importance as they
may correspond to different pathways associated with different
aspects of a cancer. In addition to these technical variances, the
limited sample size and the heterogeneity existing among the
cancer subgroups are noted as other major factors affecting the
selected markers.
In conclusion, we have demonstrated herein that gene
expression patterns can be used as effective signatures for gastric
cancer grading and staging, as well as prognostic prediction. Two
types of signatures were proposed to serve different diagnostic
purposes, each showing a certain relevance to cancer malignance
Figure 4. Correlation between gene expression (log transformed) and the pathological stages. (S1–S4 represents four stages from early
stage I to advanced stage IV.
doi:10.1371/journal.pone.0017819.g004
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PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e17819Figure 5. Average expression of three genes (CLDN7, CLDN1 and DPT) in cancer and normal samples, respectively. (A) for each
subtype (WD, MD, PD, UD); (B) for each stage (stage I, II, III and IV); and (C) the ROC curve shows the discerning power of each gene for classification of
cancer versus normal samples (AUCs of CLDN1, CLDN6 and DPT are 0.86, 0.84 and 0.79, respectively, with a significance level of P=0.0001).
doi:10.1371/journal.pone.0017819.g005
Figure 6. Distribution of expression differentials between out data and Kim dataset.
doi:10.1371/journal.pone.0017819.g006
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and stage-signatures are expected to significantly benefit the
development of personalized medicine and may lead to new serum
markers.
Materials and Methods
Tissue Samples
Samples were taken from primary malignant gastric cancers
from non-treated patients during the initial surgical procedure at
three affiliated hospitals of the Jilin University College of Medicine
and Jilin Provincial Cancer Hospital, Changchun, China. For
each cancer tissue sample, a matching reference tissue sample was
collected from the adjacent noncancerous region that the surgeon
resected in order to ensure positive margins. All samples were
snap-frozen in liquid nitrogen within 10 minutes after excision and
stored at -196C until RNA extraction. For RNA isolation, 100 mm
sections of each sample were used.
All medical records and cancer sections were examined by a
surgical pathologist, and the histological diagnosis and TNM
classification were made according to Worldwide Health Organi-
zation (WHO) criteria and the classification system of the
International Union against Cancer. The reference samples were
subjected to a meticulous histologic analysis to guarantee the
complete absence of cancer cells. Written informed consent was
obtained from all patients, which was approved by the Institutional
Review Board at the University of Georgia, Athens, Georgia, USA
and by the Chinese IRB overseeing human subjects at Jilin
University College of Medicine and the Jilin Provincial Cancer
Hospital, Changchun, China.
Detailed patient information such as age, gender, histological
type, differential grade, pathologic stage and history of using
alcohol/smoking is listed in Table S5.
Microarray experiments
The RNA samples were analyzed using the GeneChip Human
Exon 1.0 ST (Affymetrix), following the protocol detailed in the
Genechip Expression Analysis Technical Manual (P/N 900223)
for the array experiment and an earlier report [29]. The
microarrays were scanned using the GeneChipH Scanner 3000
with GeneChipH Operating Software (GCOS). All data is MIAME
compliant and the raw data has been deposited in GEO database
(ID: GSE27342).
Microarray Data Analysis
Gene expression results were summarized based on raw probe
intensities using the Robust Multichip Average [30] and the APT
package (http://www.affymetrix.com/partnerSupplementarypro
grams/programs/developer/tools/powertools.affx), following three
main steps includingbackground correction,quantile normalization
and log2-transformation. Genes having very low expression in both
cancerandreferencesampleswereremoved;specifically,a gene was
removed if its maximum(Expr.cancer, Expr.normal) was below 4
(normalized signal intensity).
Two different strategies were applied for assessing gene
significance, depending upon what conditions were compared
and whether paired or unpaired samples should be used. For
comparison of cancers against control sample groups, unpaired
tests were conducted to investigate if two groups of expression are
different, while paired tests were applied to examine the
consistency of expression changes across all pairs. In addition to
the Wilcoxon signed–rank test, we also applied another simple
statistical test to detect genes with consistent differential expression
in cancer versus reference tissues, as follows. For each gene, Kexp, the
number of pairs of cancer/reference tissues whose expression fold-
change (FC) is larger than k (e.g. k=2) was examined; if the P-
value for the observed Kexp was less than 0.05, the gene was
considered to be differentially expressed in the majority of the
cancer and reference tissue pairs (see the supporting information).
Our calculated P-value was not adjusted on the multiple
hypotheses testing in order to avoid any loss of genes that may
be potentially effective in the subsequent classification step.
Gene selection and classification
For k-gene signatures (k,=4), we conducted an exhaustive
search for all the k-gene combinations among the differentially
expressed genes, identified from the previous step, using a linear
SVM-based classification approach, and the overall accuracy was
evaluated using 5-fold cross-validation. For k.4, a different
approach using a heuristic search was applied since the exhaustive
search is too time-consuming to be practical for our problem. The
details are as follows.
The whole expression data set was randomly split into training
and test sets, each containing half of the samples. This was
repeated for 500 times to generate 500 sets of training/test data for
classification. A linear SVM was used for training a classifier
[31,32]. It constructs a hyper-plane that separates two different
classes of feature vectors with a maximum margin. This hyper-
plane is constructed by finding a vector w and a variable b that
minimize w kk
2, which satisfies the following conditions:
w:xizbwz1, foryi~z1(cancer samples) and w:xizbv{1,
yi~{1(normal samples). Here, xiis a feature vector, yiis the
group index, w is a vector normal to the hyper-plane, b jj = w kk is
the distance from the hyper-plane to the origin and w kk is the
Euclidean norm of w. After the determination of w and b values, a
given vector x can be classified by using sign(wxzb); a positive or
negative value indicates that the vector x belongs to the positive or
negative class, respectively. Gene signatures of each training set
were selected by using the recursive feature elimination procedure
(RFE), which is a wrapper that selects predictor genes by
eliminating non-predictor genes according to a gene-ranking
function generated from the classification system [33]. The
ranking criterion is based on the change in the objective function
upon removing each gene. To improve the efficiency of training,
this objective function is represented as a cost function J for the i-
th feature, computed by using the training set only. When a gene is
removed or its weight wi is reduced to zero, the change in the cost
function J(i) is given by DJ(i)~
1
2
L
2J
Lw2
i
(Dwi)
2. The case of
Dwi~wi{0 corresponds to the removal of the i-th gene. The
change in the cost function indicates the contribution of the gene
to the decision function and serves as an indicator of gene ranking.
The 500 training/test sets were randomly divided into 10
sample groups. Every sample group was then used to derive a
signature, based on majority voting and evaluation of gene-
ranking consistency across the 50 training and test sets. The 10
different signatures derived from the 10 groups were compared to
assess the level of consistency among the selected genes. In each
group, subsets of genes were selected by RFE-SVM from each
training set, and the performance on the subsets was evaluated
from the associated test set. To derive a gene ranking criterion
consistent for all iterations, a RFE ranking function at every
iteration step was derived from an SVM classifier that gave the
best average classification accuracy over the 50 test sets.
Public microarray data of gastric cancer
Two public microarray datasets were downloaded from the
GEO database for comparative studies, the Kim (GSE3438) and
Gene Signatures for Gastric Cancer
PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17819the Takeno (GSE15081) datasets. The first one [34] includes gene
expression of 50 gastric cancer patients (from Korea) at different
stages and level of differentiation, which was used to check the
consistency of our identified signatures. The Takeno data [24]
includes 141 primary gastric cancer tissues after curative surgery,
with follow-up peritoneal relapse information. These datasets
provide the normalized log2 ratio of tumor and normal expression.
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,0.05.
(XLSX)
Table S2 99 genes have their expression changes perfectly
correlate with the grades WD-MD-PD-UD (|CC|=1, p-val-
ue,0.05).
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